Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: t...
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
About this item
Full title
Author / Creator
Jacot, William , Cottu, Paul , Berger, Frederique , Dubot, Coraline , Venat-Bouvet, Laurence , Lortholary, Alain , Bourgeois, Hugues , Bollet, Marc , Servent, Veronique , Luporsi, Elisabeth , Espié, Marc , Guiu, Severine , D’Hondt, Veronique , Dieras, Veronique , Sablin, Marie-Paule , Brain, Etienne , Neffati, Souhir , Pierga, Jean-Yves and Bidard, Francois-Clement
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.
Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prior lines of chemotherapy and measurable disease. CTC with a HER2/CEP1...
Alternative Titles
Full title
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
Authors, Artists and Contributors
Author / Creator
Cottu, Paul
Berger, Frederique
Dubot, Coraline
Venat-Bouvet, Laurence
Lortholary, Alain
Bourgeois, Hugues
Bollet, Marc
Servent, Veronique
Luporsi, Elisabeth
Espié, Marc
Guiu, Severine
D’Hondt, Veronique
Dieras, Veronique
Sablin, Marie-Paule
Brain, Etienne
Neffati, Souhir
Pierga, Jean-Yves
Bidard, Francois-Clement
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_eb8133670a8c471b9655035877df2e22
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_eb8133670a8c471b9655035877df2e22
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-019-1215-z
